Survival rates at one and five years for patients with group 1 pulmonary arterial hypertension at high altitude: A retrospective cohort study
Science Progress · 2025
DOI: 10.1177/00368504251336066 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Science Progress, 2025. Verfasst von Rafael Conde-Camacho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Hypertension, Fundación Neumológica Colombiana, Bogotá, Colombia. Hauptthemen laut MEDLINE: Altitude, Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidad de La Sabana.
Abstract (Originalsprache)
Objectives
Group 1 pulmonary arterial hypertension (PAH) causes increased vascular resistance, right heart failure, and reduced survival. High-altitude PAH survival data are limited despite chronic hypoxia's potential impact on disease progression and risk stratification. The objective was to evaluate survival stratified by the European Society of Cardiology/European Respiratory Society (ESC/ERS) baseline risk score, REVEAL risk score 2.0, and etiologies in patients with PAH at high altitudes.
Methods
A retrospective cohort study was conducted to evaluate functional and hemodynamic variables and risk stratification using the ESC/ERS baseline risk score and REVEAL risk score 2.0. One-year and five-year survival rates were determined from admission to the pulmonary hypertension program until death or the end of follow-up.
Results
A total of 188 patients were included. The overall survival rate at one year was 95.8%, and at five years it was 86.8%. Precisely, 50% (95 out of 188) had congenital heart disease, 34% (63 out of 188) had idiopathic, and 13% (24 out of 188) had connective tissue disease. Risk stratification using REVEAL risk score 2.0 classified 58% (109 out of 188) of patients as low risk, 26% as intermediate risk, and 16% (30 out of 188) as high risk. Using the ESC/ERS baseline risk score, Stratification indicated 78% (146 out of 188) low risk, 21% (40 out of 188) intermediate risk, and 1% (2 out of 188) high risk. High risk according to ESC/ERS baseline risk score ( p < 0.001) and REVEAL risk score 2.0 ( p < 0.001) was associated with lower survival. Idiopathic etiology was associated with a lower survival rate ( p = 0.011).
Conclusion
The survival of patients with PAH at a high-altitude expert center was 95.8% at one year and 86.8% at five years. Risk stratification using the REVEAL risk score 2.0 and the ESC/ERS baseline risk score was associated with higher mortality in patients classified as high risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Hypertension, Fundación Neumológica Colombiana, Bogotá, Colombia.
- Department of Biosciences, Universidad de La Sabana, Chía, Colombia.
- School of Medicine, Universidad de La Sabana, Chía, Colombia.
- Department of Interventional Pulmonology, Fundación Neumológica Colombiana, Bogotá, Colombia.
ORCID-Profile: Rafael Conde-Camacho, Eduardo Tuta-Quintero, Alirio Bastidas-Goyes
Förderung
- Universidad de La Sabana
Zitieren
APA
Conde-Camacho, R., Tuta-Quintero, E., Bastidas-Goyes, A., Giraldo-Cadavid, L. F., Barón, O., & Mora, A. (2025). Survival rates at one and five years for patients with group 1 pulmonary arterial hypertension at high altitude: A retrospective cohort study. Science Progress. https://doi.org/10.1177/00368504251336066
Vancouver
Conde-Camacho R, Tuta-Quintero E, Bastidas-Goyes A, Giraldo-Cadavid LF, Barón O, Mora A. Survival rates at one and five years for patients with group 1 pulmonary arterial hypertension at high altitude: A retrospective cohort study. Science Progress. 2025. doi:10.1177/00368504251336066
BibTeX
@article{CondeCamacho2025,
author = {Conde-Camacho, Rafael and Tuta-Quintero, Eduardo and Bastidas-Goyes, Alirio and Giraldo-Cadavid, Luis F and Barón, Oscar and Mora, Angelica},
title = {Survival rates at one and five years for patients with group 1 pulmonary arterial hypertension at high altitude: A retrospective cohort study},
journal = {Science Progress},
year = {2025},
doi = {10.1177/00368504251336066}
}
EUVIMED